DEXTROAMPHETAMINE SULFATE

Post-LOE

dextroamphetamine

Noven Pharmaceuticals

ANDAORALSOLUTION

Approved

May 2013

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

3/8 — Basic

DEXTROAMPHETAMINE SULFATE (dextroamphetamine) by Noven Pharmaceuticals is clinical pharmacology amphetamines are noncatecholamine, sympathomimetic amines with cns stimulant activity. First approved in 2013.

Drug data last refreshed 22h ago

Mechanism of Action

CLINICAL PHARMACOLOGY Amphetamines are noncatecholamine, sympathomimetic amines with CNS stimulant activity. Peripheral actions include elevations of systolic and diastolic blood pressures and weak bronchodilator and respiratory stimulant action. There is neither specific evidence that clearly…

Indications

Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.

Clinical Trials (1)

NCT04132557N/ACompleted

A Study on Suicidality, Psychosis or Substance Abuse With Methylphenidate, Atomoxetine, Amphetamine/Dextroamphetamine or Lisdexamfetamine

Started Oct 2019

430,000 enrolled

Attention Deficit Disorder With Hyperactivity

Company

Worked on DEXTROAMPHETAMINE SULFATE at Noven Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.